In comments submitted last week, PhRMA cautions CMS about sweeping policy changes to the Medicaid drug rebate program, many of which are not grounded in the Medicaid statute and would go beyond CMS’ legal authority. At a time when providers, pharmacies, wholesalers and manufacturers are busy preparing for major policy changes like the average manufacturer’s price cap removal, Part D redesign, and the IRA’s price setting provisions – which all impact Medicaid – these proposed changes would be extremely disruptive if finalized.
Among the concerns outlined in our comment letter, the following rise to the top:
- The proposed "stacking” policy, which would change the calculation of best price, is inconsistent with the statute and would be operationally unworkable. The policy would require manufacturers to add up all the rebates and discounts for a unit of a medicine provided to best price-eligible entities across the entire supply chain, like pharmacies, wholesalers or providers. This new ‘best price’ based on stacking all the rebates and discounts is not a price that is actually available to any entity in the supply chain today.
- The proposed change to the “covered outpatient drug” definition would make a significant change to the Medicaid drug rebate program. Congress carefully defined covered outpatient drug when creating the Medicaid drug rebate program. This change takes the “outpatient” meaning out of “covered outpatient drug” — essentially undoing a definition that is decades old and contradicting what Congress intended.
- The proposal for a burdensome “price verification survey” does not do anything to verify the accuracy of prices reported to CMS as the rule claims. The survey would instead target manufacturers of the most innovative therapies, including cell and gene therapies, that fill a critical need in the vulnerable populations that Medicaid serves. It seeks a broad array of data – much of which is proprietary – that has nothing to do with verifying manufacturer prices reported under Medicaid. This is CMS’s not-so-veiled attempt to extract additional rebates from manufacturers without authority to do so.
The Medicaid drug rebate program plays a vital role in ensuring the financial sustainability of Medicaid and providing access to needed medicines for millions of Americans. Manufacturers pay mandatory rebates in exchange for guaranteed coverage of their FDA-approved medicines. CMS’s proposed changes far exceed the agency’s authority and jeopardize the careful balance struck by Congress in the Medicaid drug rebate statute.
Read our full comments.
Gabby Migliara
Gabby Migliara is a director of Public Affairs at PhRMA focusing on internal communications and PhRMA’s digital presence, including maintaining this website and executive social presence. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring D.C. neighborhoods.
Delivering breakthroughs and lower costs for patients
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
Ensuring access to affordable medicines for patients through Medicaid
CMS, don’t fall behind the rest of the medical community on obesity
The real cost of denying access to medicines in Medicaid
Medicaid by the numbers
Providing affordable access to medicines in Medicaid
Increased use of prior authorization in Medicaid is blocking access for patients
Manufacturers provided $42 billion in Medicaid discounts in 2021 alone
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
States can support access to medicine as COVID-19 Public Health Emergency ends
Study finds hepatitis C cure saved Medicaid $15 billion
Busting 3 Myths About Copay Coupons
Medicaid 101: Three charts on access and spending
Insurers shift medicine costs to patients with severe chronic illnesses
Tennessee’s Medicaid demonstration fails patients
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Recent administration actions undermine patient assistance programs
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
PhRMA submits comments to CMS on Medicaid proposed rule
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
New report shows better diabetes management saves money and improves patient outcomes
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
Medicaid
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA
CMS should rethink proposed changes to the Medicaid Drug Rebate Program | PhRMA